MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

Sanofi SA

Затворен

СекторЗдравеопазване

88.23 0.88

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

87.47

Максимум

88.42

Ключови измерители

By Trading Economics

Приходи

1.4B

1.9B

Продажби

3B

11B

P/E

Средно за сектора

17.216

51.198

EPS

1.79

Дивидентна доходност

4.48

Марж на печалбата

17.65

Служители

82,878

EBITDA

2.2B

2.8B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+31.16% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.48%

2.40%

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-19B

111B

Предишно отваряне

87.35

Предишно затваряне

88.23

Настроения в новините

By Acuity

39%

61%

136 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Sanofi SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.06.2025 г., 16:05 ч. UTC

Значими двигатели на пазара

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2.06.2025 г., 09:17 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2.06.2025 г., 05:31 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22.05.2025 г., 12:02 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22.05.2025 г., 00:06 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Vigil Neuroscience for About $470 Million

2.06.2025 г., 13:50 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2.06.2025 г., 12:33 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2.06.2025 г., 10:50 ч. UTC

Придобивния, сливания и поглъщания

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2.06.2025 г., 10:05 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2.06.2025 г., 05:06 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2.06.2025 г., 05:06 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2.06.2025 г., 05:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2.06.2025 г., 05:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2.06.2025 г., 05:04 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2.06.2025 г., 05:04 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2.06.2025 г., 05:03 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Blueprint Medicines Corporation

2.06.2025 г., 05:02 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Acquire Blueprint Medicines Corporation

30.05.2025 г., 08:58 ч. UTC

Горещи акции

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30.05.2025 г., 08:56 ч. UTC

Пазарно говорене

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27.05.2025 г., 05:03 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27.05.2025 г., 05:00 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21.05.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21.05.2025 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21.05.2025 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21.05.2025 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21.05.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

19.05.2025 г., 11:01 ч. UTC

Пазарно говорене

Diversified Exposure to European Banks Is Required -- Market Talk

15.05.2025 г., 11:04 ч. UTC

Пазарно говорене
Печалби

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Sanofi SA Прогноза

Ценова цел

By TipRanks

31.16% нагоре

12-месечна прогноза

Среден 114.266 EUR  31.16%

Висок 127 EUR

Нисък 95 EUR

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

17 ratings

12

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

91.3 / 96.1Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

136 / 380 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.